Results 101 to 110 of about 3,031 (144)

Simeprevir/sofosbuvir

Reactions Weekly, 2016
  +9 more sources

Simeprevir: First Global Approval

Drugs, 2013
Simeprevir (Sovriad(TM)) is a new direct-acting antiviral drug and a second-generation small-molecule NS3/4A serine protease inhibitor developed by Janssen and Medivir for the oral treatment of adults with genotype 1 and/or genotype 4 chronic hepatitis C virus (HCV) infection (chronic hepatitis C).
Asha, Vaidya, Caroline M, Perry
openaire   +2 more sources

Simeprevir/sofosbuvir

Reactions Weekly, 2015
  +7 more sources

Simeprevir

Reactions Weekly, 2016
  +4 more sources

Simeprevir

Reactions Weekly, 2017
  +4 more sources

Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice

International Journal of Antimicrobial Agents, 2022
Jin He, Hongping Wei, Hang Yang
exaly  

Application of different spectrophotometric methods for quantitative analysis of direct acting antiviral drugs simeprevir and sofosbuvir

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2022
Sherif Ramzy, Ahmed H Abdelazim
exaly  

Simeprevir/sofosbuvir

Reactions Weekly, 2017
  +5 more sources

Anti-hepatitis C virus drug simeprevir: a promising antimicrobial agent against MRSA

Applied Microbiology and Biotechnology, 2022
Pengfei She, Lanlan Xu, Linhui Li
exaly  

Simeprevir

Reactions Weekly, 2014
openaire   +1 more source